AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for October 16, 2019 meeting

IV. Secretary’s report

V. Old Business
   Update on nicotine replacement therapy utilization

VI. New Business
   A. Proposed protocol for Fabry disease products
   B. Proposed protocol for Lambert-Eaton Myasthenic Syndrome products
   C. Proposed protocol for Strensiq® (asfotase)

VII. A. Informational Highlights/Reports
    1. DXC Technology/NJ HMO 3rd Quarter 2019 Prior Authorization Report
    2. Summary of DURB Action Items
    3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
       (b) Physician-administered/Antiviral drugs by amount paid

   B. Medication information:
      (a) HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics
      (b) FDA Panel Votes 9-7 to Yank Makena Approval
      (c) Opioid, benzodiazepine coprescription slightly declines after boxed warning
      (d) FDA too slow in assessing cancer link to blood pressure drugs, watchdog says

VIII. Referenced Materials
   A. Approved protocol for Transthyretin-mediated Amyloidosis (ATTR) products
   B. Approved protocol for Gaucher disease products